• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

Economic and Healthcare Costs of Alzheimer’s Funding Delays

  • March 11, 2025
  • Pharma & Biotech
Alzheimer's research funding delays increase healthcare costs, slow drug development, and burden the economy. Explore solutions to mitigate these impacts.
Continue Reading
VASRO GmbH

UAE Economic Transformation: A Focus on AI and Healthcare in 2025

  • March 10, 2025
  • Pharma & Biotech, Tech
The UAE's economic transformation focuses on AI and healthcare investments, reducing oil dependency and positioning the nation as a global innovation leader.
Continue Reading
VASRO GmbH

Unleashing Saudi Arabia’s Healthcare Potential with Vision 2030

  • March 6, 2025
  • Pharma & Biotech
Saudi Arabia's healthcare transformation under Vision 2030 focuses on privatization, digital health, medical tourism, and global health initiatives, unlocking growth.
Continue Reading
VASRO GmbH

Plug Power’s $1 Billion Stock Deal with Yorkville Advisors and Its Impact on Green Hydrogen

  • March 5, 2025
  • Energy, Tech
Plug Power's $1B deal with Yorkville Advisors impacts the green hydrogen market, raising shareholder dilution concerns while fueling long-term growth potential.
Continue Reading
VASRO GmbH

AI and Biotechnology Working Together to Advance Healthcare

  • March 4, 2025
  • Pharma & Biotech, Tech
What are the synergies between biotech and AI? Discover how AI accelerates drug discovery, enhances diagnostics, and transforms personalized medicine.
Continue Reading
VASRO GmbH

Why Microsoft Decided to Shut Down Skype After Two Decades

  • March 3, 2025
  • Tech
Microsoft Skype shutdown in 2025 marks a shift to Teams, driven by Skype's decline and the need for a modern, cloud-based communication platform.
Continue Reading
VASRO GmbH

Analyzing biotech startup funding trends in 2025

  • March 3, 2025
  • Pharma & Biotech
Discover how venture capital drives biotech startup funding trends in 2025, focusing on gene therapy, CRISPR, and AI innovations amid regulatory shifts.
Continue Reading
VASRO GmbH

Why Tech Stock Valuations May Not Signal a Bubble in 2025

  • February 28, 2025
  • Tech
Is there a bubble in tech stock valuations? In 2025, strong fundamentals, innovation, and rational investing suggest high valuations may not signal a bubble.
Continue Reading
VASRO GmbH

Opportunities and Risks for the Technology Sector Today

  • February 27, 2025
  • Tech
Explore the technology sector challenges and opportunities in 2025, from market volatility and regulatory pressures to AI innovations and digital transformation.
Continue Reading
VASRO GmbH

The Rise of Personalized Medicine in 2025

  • February 26, 2025
  • Pharma & Biotech, Tech
Discover how pharmaceutical and biotechnology trends like AI, personalized medicine, and M&A are revolutionizing healthcare and patient outcomes in 2025.
Continue Reading

Posts pagination

Previous 1 … 24 25 26 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.